Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay
Marlyn J. Mayo(The University of Texas Southwestern Medical Center), William Rosenberg(University College London), Velimir A. Luketic(University of Padua), Guadalupe García–Tsao(Yale University), Robert Butsch(The University of Texas Southwestern Medical Center), Adrian M. Di Bisceglie, Julie Parkes(University of Southampton), James L. Boyer(Yale University), Marion G. Peters(University of California, San Francisco), Thomas Boyer(University of Arizona), David S. Barnes, Sandra Saldana(Loma Linda University), Beverley Adams‐Huet(Texas Tech University), A. Brian West(Yale University), Burton Combes(The University of Texas Southwestern Medical Center), A. Scott Mills(Virginia Commonwealth University Medical Center), Enrique Martínez(Atlanta Gastroenterology Associates), Melissa J. Contos(Virginia Commonwealth University Medical Center), Rodney S. Markin(University of Nebraska Medical Center), Raphael Rubin(Thomas Jefferson University), Donald E. Wheeler(University of South Florida), Yonas Getachew(The University of Texas Southwestern Medical Center), Nathan M. Bass(University of California, San Francisco), John R. Lake(Gilead Sciences (United States))
Cited by 199
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection
|Science|2004|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k